Skip to main content

Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA® (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types

KENILWORTH, N.J., Jun 01, 2015 (BUSINESS WIRE) — Merck MRK, -0.36% known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study.
http://www.marketwatch.com/story/findings-presented-at-2015-asco-annual-meeting-add-to-breadth-of-keytruda-pembrolizumab-data-anti-tumor-activity-now-demonstrated-in-13-different-tumor-types-2015-06-01

Disclaimer: This information is for educational purposes only, It is not to diagnose or treat your disease. If you do use the information contained on this web site without the approval of a health professional, you are prescribing for yourself, which is your constitutional right, but the author(s) and webmaster assume no responsibility

© 2022 Esophageal Cancer Education Foundation- by domino